The estimated Net Worth of Gary S Jacob is at least $54.4 Thousand dollars as of 23 March 2021. Gary Jacob owns over 2,370 units of Hepion Pharmaceuticals Inc stock worth over $16,442 and over the last 13 years he sold HEPA stock worth over $0. In addition, he makes $38,000 as Chairman of the Board at Hepion Pharmaceuticals Inc.
Gary has made over 7 trades of the Hepion Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 2,370 units of HEPA stock worth $24,695 on 23 March 2021.
The largest trade he's ever made was exercising 474,961 units of Hepion Pharmaceuticals Inc stock on 15 June 2018 worth over $237,481. On average, Gary trades about 16,317 units every 42 days since 2012. As of 23 March 2021 he still owns at least 21,922 units of Hepion Pharmaceuticals Inc stock.
You can see the complete history of Gary Jacob stock trades at the bottom of the page.
Dr. Gary S. Jacob Ph.D. serves as Chairman of the Board of the Company. From November 2018 until March 2020, Dr. Jacob served as Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. Previously, Dr. Jacob was the Chairman of the Board, President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to October 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Cardiff Oncology, Inc., a clinical-stage oncology therapeutics company. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England. Dr. Jacob’s experience as a biotechnology company chief executive officer provides him with valuable management and leadership abilities which the Board believes qualifies him to be a director of our Company.
As the Chairman of the Board of Hepion Pharmaceuticals Inc, the total compensation of Gary Jacob at Hepion Pharmaceuticals Inc is $38,000. There are 9 executives at Hepion Pharmaceuticals Inc getting paid more, with Robert Foster having the highest compensation of $621,102.
Gary Jacob is 72, he's been the Chairman of the Board of Hepion Pharmaceuticals Inc since 2014. There are 3 older and 8 younger executives at Hepion Pharmaceuticals Inc. The oldest executive at Hepion Pharmaceuticals Inc is Thomas Adams, 77, who is the Independent Director.
Gary's mailing address filed with the SEC is C/O HEPION PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON, NJ, 08837.
Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard, and John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.
hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include: